trimetrexate has been researched along with Breast Neoplasms in 13 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 9.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| " A comparison of the cell-killing effects of MTX and the nonpolyglutamable antifolate trimetrexate (TMQ) alone and in combination with 5-FU was performed to indirectly explore the role of polyglutamylation in breast cancer and bone marrow cells." | 7.70 | Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells. ( Bowen, D; Hawkins, M; Hughes, DE; Johnson, DH; Southerland, WM, 2000) |
| "We have demonstrated previously decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan (MelR MCF-7)." | 7.69 | Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan. ( Cole, D; Cowan, KH; Johnston, PG; Moscow, JA; Poplack, DG, 1995) |
| "The mechanism of acquired methotrexate-resistance in an estrogen-receptor positive human breast cancer cell line (MTX(R)ZR-75-1) was studied." | 7.68 | Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line. ( Cowan, KH; Dixon, KH; Eng, SC; Trepel, JB, 1991) |
| " Previous studies from our laboratory have shown that methotrexate accumulation into wild type (WT) ZR-75-1 human breast cancer cells involves a system with characteristics of the reduced-folate carrier, that this system is deficient in methotrexate resistant (MTXR) ZR-75-1 cells in which methotrexate transport is undetectable and that neither breast cancer cell line expresses folate receptors." | 7.68 | Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-1 human breast cancer cells. ( Chung, KN; Cowan, KH; Dixon, KH; Elwood, PC; Mulligan, T, 1992) |
| " We determined the cytotoxicity of methotrexate and the lipid-soluble antifolate trimetrexate to various human carcinoma cells and their doxorubicin-resistant sublines." | 7.67 | Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. ( Assaraf, YG; Molina, A; Schimke, RT, 1989) |
| "Trimetrexate, a nonclassical antifolate, was administered to 28 patients with progressive, metastatic breast cancer." | 7.67 | Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer. ( Leiby, JM, 1988) |
| "A total of 365 women with measurable metastatic breast cancer, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either immediate chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) or up to four cycles of one of five sequential cohorts of single-agent drugs: trimetrexate, melphalan, amonafide, carboplatin, or elsamitrucin, followed by CAF." | 5.09 | Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. ( Berry, DA; Cirrincione, C; Costanza, ME; Frei, E; Henderson, IC; McIntyre, OR; Norton, L; Schilsky, RL; Weiss, RB; Winer, E; Wood, WC, 1999) |
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 5.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| " A comparison of the cell-killing effects of MTX and the nonpolyglutamable antifolate trimetrexate (TMQ) alone and in combination with 5-FU was performed to indirectly explore the role of polyglutamylation in breast cancer and bone marrow cells." | 3.70 | Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells. ( Bowen, D; Hawkins, M; Hughes, DE; Johnson, DH; Southerland, WM, 2000) |
| "We have demonstrated previously decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan (MelR MCF-7)." | 3.69 | Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan. ( Cole, D; Cowan, KH; Johnston, PG; Moscow, JA; Poplack, DG, 1995) |
| "The mechanism of acquired methotrexate-resistance in an estrogen-receptor positive human breast cancer cell line (MTX(R)ZR-75-1) was studied." | 3.68 | Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line. ( Cowan, KH; Dixon, KH; Eng, SC; Trepel, JB, 1991) |
| " Previous studies from our laboratory have shown that methotrexate accumulation into wild type (WT) ZR-75-1 human breast cancer cells involves a system with characteristics of the reduced-folate carrier, that this system is deficient in methotrexate resistant (MTXR) ZR-75-1 cells in which methotrexate transport is undetectable and that neither breast cancer cell line expresses folate receptors." | 3.68 | Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-1 human breast cancer cells. ( Chung, KN; Cowan, KH; Dixon, KH; Elwood, PC; Mulligan, T, 1992) |
| "We have investigated the role of dihydrofolate (H2PteGlu) accumulation in the inhibition of de novo purine synthesis by methotrexate (MTX) in human MCF-7 breast cancer cells." | 3.67 | Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. ( Allegra, CJ; Baram, J; Drake, JC; Hoang, K; Yeh, GC, 1987) |
| " We determined the cytotoxicity of methotrexate and the lipid-soluble antifolate trimetrexate to various human carcinoma cells and their doxorubicin-resistant sublines." | 3.67 | Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. ( Assaraf, YG; Molina, A; Schimke, RT, 1989) |
| "Trimetrexate, a nonclassical antifolate, was administered to 28 patients with progressive, metastatic breast cancer." | 3.67 | Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer. ( Leiby, JM, 1988) |
| " The dosage schedule was single-dose intravenous administration (single treatment), followed by one or two courses of 5-day intravenous administration (5-day treatment) at 3-week intervals." | 2.67 | [Phase I study of CI-898. CI-898 Study Group]. ( Ariyoshi, H; Furue, H; Hasegawa, K; Majima, H; Nakao, I; Niitani, H; Ohta, K; Taguchi, T; Tsukagoshi, S; Yasutomi, M, 1991) |
| "Trimetrexate is a nonclassical antifol currently being tested for efficacy in cancer patients and as an antiparasitic agent against Pneumocystis carinii pneumonia in AIDS patients." | 1.28 | Hypersensitivity reactions to trimetrexate. ( Brown, TD; Costanza, ME; Grem, JL; King, SA, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, S | 1 |
| Song, L | 1 |
| Bevins, R | 1 |
| Birhiray, O | 1 |
| Moscow, JA | 2 |
| Dixon, KH | 2 |
| Trepel, JB | 1 |
| Eng, SC | 1 |
| Cowan, KH | 3 |
| Johnston, PG | 1 |
| Cole, D | 1 |
| Poplack, DG | 1 |
| Haller, DG | 1 |
| Costanza, ME | 3 |
| Weiss, RB | 1 |
| Henderson, IC | 1 |
| Norton, L | 2 |
| Berry, DA | 1 |
| Cirrincione, C | 1 |
| Winer, E | 1 |
| Wood, WC | 1 |
| Frei, E | 1 |
| McIntyre, OR | 1 |
| Schilsky, RL | 1 |
| Bowen, D | 1 |
| Southerland, WM | 1 |
| Johnson, DH | 1 |
| Hawkins, M | 1 |
| Hughes, DE | 1 |
| Mulligan, T | 1 |
| Chung, KN | 1 |
| Elwood, PC | 1 |
| Dawson, NA | 1 |
| Korzun, AH | 1 |
| Clamon, GH | 1 |
| Pollak, M | 1 |
| Vogelzang, NJ | 1 |
| Carey, RW | 1 |
| Taguchi, T | 1 |
| Tsukagoshi, S | 1 |
| Furue, H | 1 |
| Niitani, H | 1 |
| Ohta, K | 1 |
| Ariyoshi, H | 1 |
| Hasegawa, K | 1 |
| Majima, H | 1 |
| Nakao, I | 1 |
| Yasutomi, M | 1 |
| Grem, JL | 1 |
| King, SA | 1 |
| Brown, TD | 1 |
| Allegra, CJ | 1 |
| Hoang, K | 1 |
| Yeh, GC | 1 |
| Drake, JC | 1 |
| Baram, J | 1 |
| Assaraf, YG | 1 |
| Molina, A | 1 |
| Schimke, RT | 1 |
| Leiby, JM | 1 |
1 review available for trimetrexate and Breast Neoplasms
| Article | Year |
|---|---|
Trimetrexate: experience with solid tumors.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials a | 1997 |
3 trials available for trimetrexate and Breast Neoplasms
| Article | Year |
|---|---|
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
Topics: Adenine; Adult; Aged; Aminoglycosides; Analysis of Variance; Anti-Bacterial Agents; Antineoplastic C | 1999 |
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; | 1991 |
[Phase I study of CI-898. CI-898 Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Digestive System Neoplasms; Drug Administratio | 1991 |
9 other studies available for trimetrexate and Breast Neoplasms
| Article | Year |
|---|---|
The murine-reduced folate carrier gene can act as a selectable marker and a suicide gene in hematopoietic cells in vivo.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Breast Neoplasms; Carrier Proteins; Cel | 2002 |
Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Transport; Breast Neoplasms; Carrier Proteins; | 1991 |
Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan.
Topics: Breast Neoplasms; Cell Line; Drug Resistance, Multiple; Humans; Melphalan; Methotrexate; Multienzyme | 1995 |
Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; | 2000 |
Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-1 human breast cancer cells.
Topics: Biological Transport; Blotting, Northern; Breast Neoplasms; Carrier Proteins; Cell Division; Cell Me | 1992 |
Hypersensitivity reactions to trimetrexate.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Drug Hyper | 1990 |
Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate.
Topics: Acyltransferases; Antineoplastic Agents; Breast Neoplasms; Carbon Radioisotopes; Cell Line; Female; | 1987 |
Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line; Drug Resistance; Female; Gen | 1989 |
Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Humans; Middle Aged; | 1988 |